The investment-grade offering consisted of seven tranches

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a registered offering by Eli Lilly and Company of $6.75 billion aggregate principal amount of senior notes, consisting of $750 million of its Floating Rate Notes due 2028, $1 billion of its 4.000% notes due 2028, $750 million of its 4.250% notes due 2031, $1 billion of its 4.550% notes due 2032, $1.25 billion of its 4.900% notes due 2035, $1 billion of its 5.550% notes due 2055 and $1 billion of its 5.650% notes due 2065.

Eli Lilly and Company is a worldwide research-based pharmaceutical company. The company has been pioneering life-changing discoveries for nearly 150 years, and today its medicines help tens of millions of people across the globe. Eli Lilly manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its products are sold in approximately 95 countries.

The Davis Polk capital markets team included partner Yasin Keshvargar, counsel Jennifer (Ying) Lan and associate Yuchen Liu. The tax team included counsel Christopher A. Baratta and associate Jeff Metzger. The environmental team included counsel Loyti Cheng and associate Timothy J. Sullivan. The intellectual property team included partner David R. Bauer and associates Shreya R. Kundur and Elizabeth Pott. All members of the Davis Polk team are based in the New York office.

Copy link to share post